<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00375245</url>
  </required_header>
  <id_info>
    <org_study_id>14435B</org_study_id>
    <nct_id>NCT00375245</nct_id>
  </id_info>
  <brief_title>Rapamycin With Grapefruit Juice for Advanced Malignancies</brief_title>
  <official_title>A Phase Ib Study Administering Rapamycin (Sirolimus) With Grapefruit Juice in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the highest safe dose of rapamycin when given with&#xD;
      a fixed amount of grapefruit juice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic interaction</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Tumors</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Rapamycin + Grapefruit juice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin (sirolimus)</intervention_name>
    <description>Weekly oral doses, dose is assigned at the time of study entry</description>
    <arm_group_label>Rapamycin + Grapefruit juice</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Grapefruit Juice</intervention_name>
    <description>Daily oral doses starting during the second week on study.</description>
    <arm_group_label>Rapamycin + Grapefruit juice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed malignancy that is metastatic or unresectable and for which&#xD;
             standard curative or palliative measures do not exist or are no longer effective.&#xD;
&#xD;
          -  Patients with hematologic malignancies (lymphoma, multiple myeloma and chronic&#xD;
             lymphocytic leukemia (CLL) only) are eligible to participate in the phase IB portion&#xD;
             of the trial only.&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy or radiation therapy&#xD;
&#xD;
          -  Aged 18 years or older&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy of greater than 3 months.&#xD;
&#xD;
          -  Normal organ and marrow function:&#xD;
&#xD;
               -  No transfusions of packed red blood cells within 1 week of starting treatment&#xD;
&#xD;
               -  Leukocytes greater or equal to 3,000/μL&#xD;
&#xD;
                  ** White blood cell (WBC) greater or equal to 1,500/μL for patients with&#xD;
                  hematologic malignancies&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) greater or equal to 1,500/μL&#xD;
&#xD;
                  ** ANC greater or equal to 1,000/μL for patients with hematologic malignancies&#xD;
&#xD;
               -  Platelets (PLT) greater or equal to 100,000/μL&#xD;
&#xD;
                  ** PLT greater or equal to 50,000/μL for patients with hematologic malignancies&#xD;
&#xD;
               -  Total bilirubin within normal institutional limits&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) less than or equal to 2.5 times institutional upper&#xD;
                  limit of normal&#xD;
&#xD;
               -  Serum triglycerides less than or equal to 500 mg/dl&#xD;
&#xD;
               -  Creatinine within normal institutional limits OR creatinine clearance greater or&#xD;
                  equal to 60 mL/min for patients with creatinine levels above institutional normal&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence)&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C)&#xD;
             prior to entering the study or those who have not recovered from adverse events due to&#xD;
             agents administered more than 4 weeks earlier.&#xD;
&#xD;
          -  May not be receiving any other investigational agents.&#xD;
&#xD;
          -  Uncontrolled brain metastases or malignancy. Cannot be receiving enzyme-inducing&#xD;
             anticonvulsants.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to rapamycin&#xD;
&#xD;
          -  Gastrointestinal malabsorption syndromes, partial small bowel obstruction, or any&#xD;
             illness that would interfere with the ability to absorb oral medications.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness&#xD;
&#xD;
          -  Severe immunodeficient states (as judged by the treating physician)&#xD;
&#xD;
          -  Pregnant women are excluded from this study; breastfeeding should be discontinued.&#xD;
&#xD;
          -  HIV-positive patients receiving combination antiretroviral therapy are excluded.&#xD;
&#xD;
          -  Concurrent use of ketoconazole, cyclosporine, tacrolimus, diltiazem, and rifampin with&#xD;
             rapamycin is not permissible. The concurrent use of calcium channel blockers,&#xD;
             terfenadine, astemizole, cisapride, propafenone, cyclosporine, midazolam, triazolam,&#xD;
             quinidine, or theophylline with grapefruit juice is not permissible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ezra W Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Hospitals</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>September 11, 2006</study_first_submitted>
  <study_first_submitted_qc>September 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2006</study_first_posted>
  <last_update_submitted>January 16, 2014</last_update_submitted>
  <last_update_submitted_qc>January 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>phase I</keyword>
  <keyword>metastatic</keyword>
  <keyword>advanced cancer</keyword>
  <keyword>lung cancer</keyword>
  <keyword>renal cancer</keyword>
  <keyword>kidney cancer</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>breast cancer</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>esophagus</keyword>
  <keyword>GIST</keyword>
  <keyword>liver cancer</keyword>
  <keyword>melanoma</keyword>
  <keyword>mesothelioma</keyword>
  <keyword>lymphoma</keyword>
  <keyword>ovary cancer</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>pancreas cancer</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>stomach cancer</keyword>
  <keyword>thyroid cancer</keyword>
  <keyword>Metastatic solid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

